The clinical PI3K inhibitor NVP-BEZ235 induces N-Myc degradation, inhibits angiogenesis, and prolongs survival in MNA-NB, including in humans and transgenic mouse models (Chanthery et al., 2012; Vaughan et al., 2016). Here, MYCN is linked to neuroblastoma.